A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

What is the purpose of this trial?

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.



NextCure, Inc.

Start Date: 05/07/2019

End Date: 09/01/2020

Last Updated: 06/18/2019

Study HIC#: 2000023979

Get Involved

For more information about this study, contact:
Nicole Sinclair
+1 203-737-1889
nicole.sinclair@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image